Mawson Graham - Australian Small-Cap Research
  • Home
  • About
  • Analyst Research
  • Guides
  • Online Platform
  • Contact
Access Research
  1. Home
  2. Research
  3. Reports
  4. ASX:CDY

ASX:CDY - Cellmid Ltd Research

Multiple Near Term Growth Triggers

CDY ASX Small Cap Research
Company Overview

Cellmid produces évolis®, which has been one of the best selling haircare products of all time on QVC with 33,000 repeat customers in Japan and is poised for further growth. Cellmid is also aiming to commercialise a Rapid Coronavirus Rapid Test in the Australian market after signing a supply agreement with Guangzhou Wondfo Biotech.

Release Date (3 years ago)
  •   May 10th, 2019
All CDY Reports
  • August 16th, 2019
  • May 10th, 2019
Report Includes
  • Recent events
  • Investment highlights
  • Analyst's view
  • Consensus targets
  • More...
Analyst
SmallCapInsider
 Research
Download Report

We believe Cellmid’s FGF5 inhibition assets give them a compelling USP in the global competitive landscape for the US$7bn hair loss and US$24bn anti-aging haircare markets. Hair loss and poor hair quality are increasingly becoming problems caused by poor lifestyle choices and environmental factors (such as stress and nutritional deficiencies), rather than being driven purely by genetics and the aging process.

Of great significance is the fact that 40% of women have visible hair loss by the time they are aged 40, which has serious negative consequences to an individual’s psychological and emotional wellbeing. Also, Cellmid’s products, based on 100% natural actives, should benefit from the shift of consumers towards products which have natural ingredients.

We believe there are multiple triggers for growth each which could have a material impact on sales or the valuation of the company.

Some of these triggers include:

  • Continued expansion of sales into the United States by launching in additional high-end retail outlets, such as NeimanMarcus and Bloomingdales. 
  • An expansion of the existing partnership with QVC Japan, such as via QVC China and QVC Germany.  
  • Entering into additional foreign markets such as China through their partnership with Fukagren.
Download Report
Mawson Graham - ASX Research

1300 131 551 [email protected]

Mawson Graham
Level 33, 264 George St
New South Wales 2000
Australia

Connect with us:

Mawson Graham Pty Ltd (ABN 53 631 737 650) is Corporate Authorised Rep (CAR) of Vested Equities Pty Ltd (ABN 54 601 621 390) Australian Financial Services (AFS) Licence 478987. The content on this website is for general information purposes only and is not intended to reflect any recommendations or financial advice. The information on this site has been prepared without taking into account your objectives, financial situation or needs. For this reason, you should consider the appropriateness of the advice or recommendation in light of your own personal circumstances, relevant risk factors, the nature and extent of your risk of loss, as well as the legal and accounting consequences before acting making an investment or trading decision regarding any Financial Product mentioned herein. While it is believed that all information sourced and contained on this website to be accurate at the time of publication, liability for any errors, omissions, accuracy or completeness of the information (except any statutory liability which cannot be excluded) is specifically excluded by Mawson Graham, its associates, officers, directors, employees and agents. Past performance is not a reliable indicator of future performance. Important Disclosure: Mawson Graham Pty Ltd, its directors, associates and employees advise that they may hold securities, may have an interest in and/or earn brokerage, corporate and/or investor relations fees, and other benefits or advantages, either directly or indirectly from client transactions arising from any information mentioned on this website and in documents published to this website. Directors, associates and employees of Mawson Graham Pty Ltd from time to time may hold shares in the security/securities mentioned on this website and in documents published on this website and, therefore, may benefit from any increase in the price of those securities.

© 2022 Mawson Graham All Rights Reserved
Terms Privacy FSG Transparency